Cidara Therapeutics, Inc. (20D.F)
- Previous Close
0.5660 - Open
0.4998 - Bid 0.4492 x 40000
- Ask 0.5115 x 40000
- Day's Range
0.4780 - 0.4998 - 52 Week Range
0.4780 - 26.7200 - Volume
17,880 - Avg. Volume
52 - Market Cap (intraday)
2.181M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-97.5800 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.04
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
www.cidara.comRecent News: 20D.F
Performance Overview: 20D.F
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 20D.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 20D.F
Valuation Measures
Market Cap
43.87M
Enterprise Value
14.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.04
Price/Book (mrq)
7.31
Enterprise Value/Revenue
0.23
Enterprise Value/EBITDA
-0.61
Financial Highlights
Profitability and Income Statement
Profit Margin
-35.88%
Return on Assets (ttm)
-26.70%
Return on Equity (ttm)
--
Revenue (ttm)
63.91M
Net Income Avi to Common (ttm)
-22.93M
Diluted EPS (ttm)
-97.5800
Balance Sheet and Cash Flow
Total Cash (mrq)
35.78M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
9.14M
Research Analysis: 20D.F
Company Insights: 20D.F
20D.F does not have Company Insights